6,245 trials (keyword fallback)
Renal Impairment · Tuberculosis
Primary: Fold Change in Pretomanid AUC(0-last) in Participants With Renal Impairment as Compared to Matched Healthy Controls — 77130; 63600; 62660 ng*h/mL
Migraine
Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 259; 293 nanogram per milliliter (ng/mL)
Pain · Opioid Use, Unspecified, Uncomplicated
Primary: Quality of Recovery Scores Post Operative — 183; 159 units on scale 40 (low) - 200 (high)
Infections, Bacterial
Primary: Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1 — 14838; 22367; 28545 Nanogram*hour per milliliter
Type1diabetes · Type1 Diabetes Mellitus · Diabetic Kidney Disease
Primary: Renal Oxygenation — 22.4; 22.5 s^-1
Type 2 Diabetes · Overt Diabetic Nephropathy
Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
Abscess · Fracture
Primary: Median Effective Dose (ED50) and ED95 of Rapidly Administered Ketamine — 0.7; 0.5; 0.6; 0.9 mg/kg of ketamine dose
Graft Rejection · Kidney Disease
Primary: Number of Patients With Renal Allograft Rejection — 5 participant
End-stage Renal Disease
Primary: Chronic Allograft Nephropathy (Cumulative Calcineurin-inhibitor Nephrotoxicity/Transplant Nephropathy) Per Protocol Surveillance Kidney Biopsies (Banff Grading…
Immunosuppression
Primary: Mean International Society for Heart and Lung Transplantation Biopsy Score Over the First 6 Months Post-transplantation — 0.7; 0.65 units on a scale
End Stage Renal Disease · Kidney Transplantation
Primary: Cumulative One-year Acute Rejection Rates — 7 Participants — p=0.28
Kidney Cancer
Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter
Substance Use
Primary: Number of Participants Reporting Substance Use — 38; 45; 8; 9 Participants